| Document |
Document Title |
|
JP3030152B2 |
PURPOSE: To obtain a new compound, having excellent inhibiting action on a testosterone 5α-reductase and useful for prostatic hypertrophy. CONSTITUTION: The objective compound of formula I [R1 is H or (substituted)1-6 C alkyl; R2 is (su...
|
|
JP3029719B2 |
PURPOSE: To obtain the subject derivative having high plant-growth regulating activity, effective at a low rate of application and useful in the field of agricultural and biological chemistry by lactonizing the B-ring ketone of a 2- deox...
|
|
JP2000063398A |
To efficiently obtain a high-purity labeled steroid from an obtainable general-purpose compound as a raw material useful for elucidating an organism function, etc., in a high yield by catalytically deuterating or catalytically tritiating...
|
|
JPH11515001A |
PCT No. PCT/DE96/01958 Sec. 371 Date Apr. 13, 1998 Sec. 102(e) Date Apr. 13, 1998 PCT Filed Oct. 11, 1996 PCT Pub. No. WO97/14683 PCT Pub. Date Apr. 24, 1997The invention relates to phenanthridine derivatives of the general formula I and...
|
|
JPH11514648A |
The compounds of formula (I) are useful as immunosuppressive agents.
|
|
JPH11513981A |
The compounds of the present invention are those of structural formula (I) wherein X is oxygen or sulfur. Pharmaceutical compositions and methods of use of the compounds in the treatment of hyperandrogenic conditions are disclosed. In ad...
|
|
JPH11513684A |
Compounds of the formula I I are inhibitors of 5 alpha -reductase, and are useful for the treatment of hyperandrogenic disorders such as acne vulgaris, seborrhea, female hirsutism, male pattern baldness, prostatic carcinoma, prostatitis ...
|
|
JPH11513711A |
The novel compounds of the present invention are those of structural formula (I), or a pharmaceutically acceptable salt, or stereoisomer thereof, which are inhibitors of 5 alpha -reductase, particularly 5 alpha -reductase type 1. The com...
|
|
JP2980992B2 |
|
|
JPH11512434A |
Compounds of structural Formula (I), and pharmacologically acceptable salts and esters thereof possess 5 alpha -reductase inhibitory activity. These compounds inhibit 5 alpha -reductase type 1 and type 2. The compounds of structural Form...
|
|
JP2959839B2 |
Methods for treating sex steroid-dependent diseases by inhibiting sex steroid activity include administration of novel compounds which include an androgenic nucleus substituted at a ring carbon with at least one substituent specified her...
|
|
JP2904310B2 |
The present invention relates to the compound of formula (I), (I) also known as 17 beta -N-(2,5-bis(Trifluoromethyl))phenylcarbamoyl-4-aza-5 alpha -androst-1-en-3-one, solvates thereof, its preparation, intermediates used in its preparat...
|
|
JPH11100396A |
To obtain the subject therapeutic agent for alopecia, female hirsutism and seborrhea, a preventive for bone metastasis of prostatic cancer, having lowering action on dihydrotestosterone in the blood, by using a specific steroid- based co...
|
|
JP2863786B2 |
The present invention is an oxidative process for the conversion of 21-unsaturated progesterones (I) to the corresponding 3,5-secoandrost-5-one-3,17 beta -dioic acids (II) by use of either ozone or an oxidizing agent, which are useful in...
|
|
JP2862376B2 |
Compounds of the Formula Iare inhibitors of the 5alpha-reductase 1 isozyme, and are useful alone, or in combination with a 5alpha-reductase 2 inhibitor, for the treatment of androgenic sensitive disorders such as acne vulgaris, seborrhea...
|
|
JP2858471B2 |
|
|
JPH10316700A |
To obtain the subject compound exhibiting an excellent antioxidizing activity, difficult to receive metabolism-inactivating actions, and useful for preventing or treating diseases to which active oxygen or lipid peroxides relate, by intr...
|
|
JPH10512275A |
PCT No. PCT/US96/00055 Sec. 371 Date May 6, 1997 Sec. 102(e) Date May 6, 1997 PCT Filed Jan. 12, 1996 PCT Pub. No. WO96/22100 PCT Pub. Date Jul. 25, 1996Compounds of the formula I are inhibitors of 5 alpha -reductase and are useful alone...
|
|
JPH10511958A |
The invention concerns the treatment of hyperandrogenic conditions in humans by the formation of a novel mechanism-based irreversible inhibitor of human 5 alpha -reductase enzymes from 3-oxo-4-azasteroids having a 1,2-double bond and the...
|
|
JPH10298081A |
To obtain a medicine capable of treating or preventing prostatic cancer, by including a carboxamide derivative. This medicine contains a compound of the formula (R1 and R2 are each H, OH or a lower alkoxy), its salt or its another deriva...
|
|
JPH10509188A |
Compounds of formula (I), wherein: the symbol +E,uns ----+EE represents a single or a double bond; R is a hydrogen atom or a C1-C4 alkyl group; Rf and R'f, each independently, are C1-C4 alkyl groups substituted by one or more fluorine at...
|
|
JPH10507755A |
Compounds of the Formula I I wherein: the dotted line indicates that a double bond may be present or absent; R1 is H, methyl or ethyl; R2 is alpha - or beta -C1-10 straight or branched alkyl; R3 is CO2H, CN, CO2R4, COHNR4, or CON(R4)2; R...
|
|
JPH10507451A |
A process of providing novel compounds of Formula (I), that are useful as 6-azaandrostenone testosterone 5-alpha-reductase inhibitors, from commercially available compounds of Formula (II) +TR wherein the substituents are as defined in t...
|
|
JPH10506411A |
The present invention relates to the epimers: (22R)-N-(1,1,1-trifluoro-2-phenylprop-2-yl)-3-oxo-4-aza-5 alpha -androst-1-ene-17 beta -carboxamide and (22S)-N-(1,1,1-trifluoro-2-phenylprop-2-yl)-3-oxo-4-aza-5 alpha -androst-1-ene-17 beta ...
|
|
JP2742409B2 |
Disclosed is a new process for producing finasteride which involves reacting the magnesium halide salt of 17β-carboalkoxy-4-aza-5α-androst-1-en-3-one with t-butylamino magnesium halide, present in at least a 2:1 molar ratio to the este...
|
|
JP2741286B2 |
Androgen nucleus derivatives having specified substituents at the 17 alpha position are disclosed for use as antiandrogens for the treatment of androgen-dependent diseases. In some preferred embodiments, the compound EM-250 is formulated...
|
|
JPH1081625A |
To obtain a medicinal composition useful for treatment of prostatic adenocarcinoma by containing a depressant compound for steroid 5-α-reductase and a medicinally permissible carrier. As a compound of steroid 5-α-reductase inhibitor, 1...
|
|
JPH1067778A |
To obtain the subject new compound which is selective estrogen receptor modulator and useful for treating estrogen-related disorder such as postmenopausal syndrome, osteoporosis or hyperlipemia. This compound is represented by formula I ...
|
|
JP2702280B2 |
Invented is a Method of Treating Prostatic Adenocarcinoma by employing asteroid 5- alpha -reductase inhibiting compound or a combination of steroid 5- alpha -reductase inhibiting compounds.
|
|
JPH10500682A |
The instant invention involves a process for oxidizing compounds containing an allylic group, i.e. those containing an allylic hydrogen or allylic alcohol group, to the corresponding enones, using a ruthenium-based catalyst in the presen...
|
|
JPH09512535A |
Compounds of the formula are inhibitors of 5 alpha -reductase and are useful alone or in combination with other active agents for the treatment of hyperandrogenic disorders such as acne vulgaris, seborrhea, female hirsutism, male pattern...
|
|
JP2660404B2 |
1. The products of formula I : see diagramm : EP0245170,P90,F1 in which R1 represents an alkynyl radical having from 2 to 8 carbon atoms optionally substituted by a radical selected from the radicals, hydroxyl, halogen, trialkylsilyl, al...
|
|
JP2617706B2 |
New steroid compounds of the general formula: (A) wherein X is a hydroxyl group and Y is a hydrogen atom, or X and Y, taken together, form an oxo group; each of the two R' radicals is independently a hydrogen atom, acyl group, a silyl gr...
|
|
JPH09504553A |
Compounds of formula (I) are inhibitors of 5 alpha -reductase and are useful alone or in combination with 5 alpha -reductase 1 and/or 2 inhibitors for the treatment of hyperandrogenic disorders such as acne vulgaris, seborrhea, female hi...
|
|
JPH09503227A |
PCT No. PCT/EP95/02649 Sec. 371 Date May 31, 1996 Sec. 102(e) Date May 31, 1996 PCT Filed Jul. 7, 1995 PCT Pub. No. WO96/03422 PCT Pub. Date Feb. 8, 1996The present invention provides compounds of formula (D wherein the symbol +E,uns - -...
|
|
JP2591640B2 |
|
|
JP2592870B2 |
The compounds of formula (I) wherein R is selected from hydrogen, methyl or ethyl, and R<1> is C1-12 straight or branched chain alkyl wherein one of the hydrogens is substituted by hydroxy, carboxylic acid or C1-4 alkyl ester, and A is -...
|
|
JP2575310B2 |
|
|
JP2564576B2 |
Disclosed herein is a novel brassinosteroid derivative represented by the formula: wherein R3 represents C1-2-alkyl, R1 and R2 which may be the same or different, represent hydrogen or acyl, respectively, otherwise R1 and R2, combining t...
|
|
JP2547322B2 |
|
|
JP2538489B2 |
PURPOSE: To prepare a medicament composed of a new testosterone-5α-reductase inhibiting compd. and useful for the prevention of prostatic carcinoma for patients free from the symptom of prostatic carcinoma. CONSTITUTION: The objective m...
|
|
JP2512388B2 |
PURPOSE: To obtain the subject compound having a specific formula, useful as an intermediate for preparing an aza-steroid or a radioactively labeled GABA-receptor substance. CONSTITUTION: This intermediate is expressed by formula I (A is...
|
|
JP2512389B2 |
PURPOSE: To obtain the subject compound having a specific formula, useful as an intermediate for preparing an aza-steroid or a radioactively labelled GABA-receptor substance. CONSTITUTION: This intermediate is expressed by formula I (A i...
|
|
JP2512390B2 |
PURPOSE: To obtain the subject compound having a specific formula, useful as an intermediate for preparing an aza-steroid or a radioactively labelled GABAreceptor substance. CONSTITUTION: This intermediate is expressed by formula I (A is...
|
|
JPH08157370A |
PURPOSE: To obtain the subject composition capable of administering a pharmacodynamically effective ingredient at a constant rate for a long period in release behavior of zero order without causing the initial burst of the pharmacodynami...
|
|
JPH08504813A |
PCT No. PCT/US93/11155 Sec. 371 Date Jun. 2, 1995 Sec. 102(e) Date Jun. 2, 1995 PCT Filed Nov. 18, 1993 PCT Pub. No. WO94/14452 PCT Pub. Date Jul. 7, 1994The present invention is concerned with the use of 17 beta -N-monosubstituted-carba...
|
|
JPH08504825A |
The present invention relates to certain substituted 17 beta -substituted carbonyl-6-azaandrost-4-en-3-ones of formula (I), wherein R<1> and R<2> i) are independently hydrogen or lower alkyl and the bond between the carbons bearing R<1> ...
|
|
JPH08503473A |
Invented are novel 17 alpha -acyl steroidal 5 alpha -reductase inhibiting compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5- alpha -reductase. Also invented are ...
|
|
JPH0830077B2 |
|
|
JPH0873486A |
PURPOSE: To obtain the subject new derivative, isolated from a cultured mycelium of Hericium erinaceum Pers. which is a mushroom belonging to the genus Hericium of the family Hydnaceae, having the cyathane skeleton, capable of manifestin...
|
